|
Post by kc on Jun 15, 2017 18:39:28 GMT -5
Dr. Edelman of TCOYD
|
|
|
Post by kc on Jun 15, 2017 15:07:13 GMT -5
the Caravan is leaving Danbury as we are hitting send today.
|
|
|
Post by kc on Jun 15, 2017 15:03:50 GMT -5
Apparently the truth hurts. No rebuttals....? Someone give me a reason not to cut my losses and take a tax loss carry forward for the next 13 years. Do us all a favor and don't let the door hit you as you leave.
|
|
|
Post by kc on Jun 11, 2017 21:17:27 GMT -5
Social media is in and the status quo just doesn't get it yet. Big Pharma is like old media newspapers and TV news reporting.
Glad that Mike C. And the board understand the new realities of social media in 2017. Let the old guard continue to wonder about the new normal and Paradim shift taking place.
The old stodgy ADA can't control social media.
|
|
|
Post by kc on Jun 7, 2017 21:49:06 GMT -5
If you are correct and nothing but DTC matters they should be cancelling the booth. However, the real value at ADA are the backroom deals. I fully expect Apple and Onduo and Microsoft and Amazon will be walking the floor and having meetings. ADA 77 has nothing to do with DTC. You have to be there because your competitors are also exhibiting there. If you do not show up and have a booth, then you are not considered to even be in the market. It was a good choice to go ahead and get a booth at ADA 2017
|
|
|
Post by kc on Jun 7, 2017 12:10:38 GMT -5
That is the crazy thing. It appears there is no interest from the medical TV shows (Doctors, etc...) with an FDA approved drug that would eliminate the need to poke yourself with needles. Hopefully scripts will pick up with DTC and the medical world will be calling Mike for interviews. Well that is my hope.... That seems a bit bass-ackwards to me. The CEO needs to be pushing the media for interviews rather than waiting for the phone to ring.
Perhaps after MannKind and One Drop sign a Collaboration Agreement, both Castagna and Dachis will hit the circuit. Both of these gentlemen are enthusiastic, experienced speakers. It would be fascinating to watch them in action together.
You can bet that in time Mike C will be doing just that plan. They have to start somewhere and he has building his team. you know that is on his agenda. The new MannKind will be more transparent if they get to that stage.
|
|
|
Post by kc on Jun 7, 2017 11:50:26 GMT -5
That is the crazy thing. It appears there is no interest from the medical TV shows (Doctors, etc...) with an FDA approved drug that would eliminate the need to poke yourself with needles. Hopefully scripts will pick up with DTC and the medical world will be calling Mike for interviews. Well that is my hope.... They don't want to bite the hand that feeds them. ADVERTISING DOLLARS.
|
|
|
Post by kc on Jun 7, 2017 9:17:01 GMT -5
You first hire folks you know. That would be why Mike possibly hired this man. Has the background we need at MannKind.
Experience Amgen Director of Global Marketing Company Name Amgen Dates Employed Oct 2013 – Present Employment Duration •3 yrs 9 mos Amgen Senior Marketing Manager Company Name Amgen
Dates Employed Mar 2009 – Oct 2013
Employment Duration •4 yrs 8 mos Amgen Sr. Biopharmaceutical Sales Representative Company Name Amgen Dates Employed Nov 2006 – Mar 2009 Employment Duration •2 yrs 5 mos
Featured Skills & Endorsements Pharmaceutical Industry See 25 endorsements for Pharmaceutical Industry · 25
Endorsed by 13 of Johnny’s colleagues at Amgen Product Launch See 19 endorsements for Product Launch · 19 Oncology See 18 endorsements for Oncology · 18 Pharmaceutical Sales See 17 endorsements for Pharmaceutical Sales · 17
Biotechnology See 13 endorsements for Biotechnology · 13
Sales Effectiveness See 10 endorsements for Sales Effectiveness · 10
Cross-functional Team Leadership See 9 endorsements for Cross-functional Team Leadership · 9
cardiology See 7 endorsements for Cardiology · 7 Biopharmaceuticals See 6 endorsements for Biopharmaceuticals · 6
Neurology See 6 endorsements for Neurology · 6
Rheumatology See 4 endorsements for Rheumatology · 4
Commercialization See 4 endorsements for Commercialization · 4
Market Access See 3 endorsements for Market Access · 3
Hematology See 2 endorsements for Hematology · 2
Hospital Sales See 2 endorsements for Hospital Sales · 2
Urology See 2 endorsements for Urology · 2
|
|
|
Post by kc on Jun 7, 2017 7:42:03 GMT -5
Looks like we are getting ANOTHER guy Directly from AMGEN ... Keep a Lookout for a Guy Named Johnny Chung ...currently working at AMGEN Cryptic Tweet from our New CEO leads me to believe he will on board soon... Hmmm..that Looks like 4 ...count em 4 AMGEN guys on the Mannkind Train (yeah I know Appel is gone already) You hire folks you know and have worked with before. That is very common in the business world.
|
|
|
Post by kc on Jun 6, 2017 20:49:18 GMT -5
It may be that MNKD has a potential partner that's been dragging their feet in hopes of renegotiating a more lucrative deal by employing delay tactics. By signing up Locust Walk to assist this might create urgency to move as other suitors may be lurking in the shadows. Creating a position of strength. Just a thought. Mike said at the shareholders meeting he was looking to partner in the U.S. to address the PCP T2 market with a sales force of 300-500. He sounded like he already had someone in mind. IMO Amgen does not fit the bill but this might www.diabetescare.abbott/index.htmlMNKD mentioned doing time in range studies with Abbott and Mike just mentioned Abbott and their "new product" in the 6/5 posted interview. Abbott already going into PCPs to sell the new Libre combined with afrezza is the perfect fit, IMO. I AGREE with SAYHEY24. Based on what I heard and saw on Saturday The TYPE 2 market might be the Holy Grail of treatment. Listening to both Mike's Pharmacy interview, The ASM panel and Dr. Edelman on Saturday. The most uncompliant diabetic is the Type 2. Especially the one who has avoided treatment until they were really sick. At some time in the past Al Mann referred to these Type 2 folks as being in the lost decade of treatment. MannKind is addressing this with the way they have been talking about TITRATION regiments. Mike himself said in the Pharmacy clip that you can take Afrezza right at meal time and it works within 15 mins instead of more than an hours for injected Insulin. That the patient could take a follow up dose based on their CGM numbers. Interesting enough Edelman was very high on the Abott product and thought it would be an over the counter device within a short time like it was in other markets with the exception of the USA. He said it was silly or sad that a patient had to use the Libre currently by having to go to the Endo for calibration and reading. He said that it would enable patients to be active in their own treatment. So it fits the narrative that perhaps there might be some type of alliance between Mannkind and Abbott's sales team. We all know that something good is in our future.
|
|
|
Post by kc on Jun 6, 2017 18:52:24 GMT -5
I am hoping that the Rite Aid buy out by Walgreens falls apart that Amazon buys Rite Aid .
Rite Aid is very cheap these days. If the Walgreens deal goes through it's at $6.50 or $6.75. Today is closed at $3.47
|
|
|
Post by kc on Jun 6, 2017 15:07:06 GMT -5
Fidelity is charging now 70.75% seems like a great deal if you need shares to short.
|
|
|
Post by kc on Jun 6, 2017 11:45:01 GMT -5
wake me up when we reach 1,000,000 shares for the day.
|
|
|
Post by kc on Jun 6, 2017 10:53:31 GMT -5
Peppy,
You get it right Doctors are basically lazy and not tuning into what the patient needs. My TCOYD experience opened my eyes as to why Mannkind has to shake things up a bit. This is going to be are your PASSIVE about your treatment or ACTIVE about it. This Dr. Edelman gets it and is trying to teach HCP and patients you need to manage your own outcomes if you want to stay healthy and live a long life.
I posted the following yesterday on the ASM thread. -- The big Pharma companies are wanting to just keep folks dependent on their products. If it works doctors just keep prescribing them in a step therapy basis. Mike also says it very clearly in his Pharmacy edge interview. He words are very similar to what Edelman said.
From the ASM thread: I can see how Matt might not have been on board with the non-traditional hipster type approach. But marketing Afrezza in the same old manner that all Pharma companies are using is not getting us visibility and we all know this is a product that is having a tough time being scene as doctors are not into change.
Afrezza is a real Paradigm change for treatment. Doctor's don't get it and the don't care to get it as long as their patients are passive and accept what treatment they are receiving. The whole concept of TCOYD is to be an active participant in their own treatment.
I saw that for my very eyes that this weekend at the TCOYD event. One of the sessions I attended was with Dr. Edelman it was titled
Patients vs. Providers: Why Are We at Odds About Medications? Steven V. Edelman, MD, and William Polonsky, PhD, CDE
in this session you had both patients, Doctors, nurses, it was a full rooms and you can understand why folks are frustrated with their level of treatment. I wish that I took notes or picture of the comments. There is so much product in the Diabetes market that doctors are confused in what to prescribe. They use all the basic step therapies first and Afrezza is not on their steps. Yet!
The TCOYD event showcased all the products. So while we think Afrezza is the Holy Grail for treatment we have to know that the doctors have possibly too many options so they stick to what they are familiar with and easy to prescribe. Dr. Edelman even stated that when talking in the general session about treatment options.
AFREZZA is not for the passive patient who is just doing whatever the DR says. Its for the Patient who is TAKING CONTROL OF THEIR OWN TREATMENT.
We need to attack the problem with visibility in a new manner and the board must have believed that Mike Castagna got it and knows the right direction to move MannKind forward.
Read more: mnkd.proboards.com/thread/8006/video-asm?page=2#ixzz4jEoQlnh5
|
|
|
Post by kc on Jun 6, 2017 10:26:07 GMT -5
Diabetes Burn out, non-compliance, Did this to help the tens of millions of diabetics, 70% are not below 7 AIC, Not changed in 20 years. Main stream used up front. Afrezza patient seeing sugars dropping in 5 mins vs waiting for one hour. I'm an impatient person. So are most diabetics. impact on Spouse and child.
Letters saying thank you. World of mouth is best form of advertising. Its a matter of getting doctors to try it.
|
|